Actively Recruiting
Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment
Led by Centre for Addiction and Mental Health · Updated on 2026-03-10
150
Participants Needed
3
Research Sites
207 weeks
Total Duration
On this page
Sponsors
C
Centre for Addiction and Mental Health
Lead Sponsor
K
Krembil Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to validate the Creyos online cognitive assessment platform in individuals with mild cognitive impairment, or remitted major depressive disorder. The main objectives of this research are: 1. To confirm the feasibility of administering the Creyos cognitive battery to older adults with Mild Cognitive Impairment MCI) or Major Depressive Disorder in remission (rMDD). 2. To determine whether the Creyos battery can detect changes in cognition that are predictive of changes on paper-and-pencil neuropsychological testing ("gold standard") over up to five years. Participants will complete both in-person neuropsychological testing yearly as well as the Creyos online battery quarterly for up to 5 years, to allow us to compare performance on these two batteries over time.
CONDITIONS
Official Title
Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to read and communicate in English
- Availability of a study partner who has regular contact with the participant
- For MCI group: Aged 60 or older and meets DSM 5 criteria for Minor Neurocognitive Disorder (MCI)
- For rMDD group: Aged 65 or older and meets DSM 5 criteria for one or more major depressive episodes during adult life with specific offset criteria
- For control group: Aged 60 or older
You will not qualify if you...
- Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD
- Diagnosis of alcohol or substance use disorder within past 12 months
- High risk for suicide
- Significant neurological conditions such as stroke, seizure disorder, or multiple sclerosis
- Unstable medical illnesses like uncontrolled diabetes or hypertension
- Taking anticonvulsants or psychotropic medications that interfere with cognitive testing and cannot be safely stopped
- Current depressive symptoms with MADRS score of 10 or above
- For MCI group: Use of cognitive enhancers within past 6 weeks
- For rMDD group: Use of cognitive enhancers within past 6 weeks or electroconvulsive therapy within 6 months
- For control group: Meets DSM 5 criteria for MDD or MCI at any time in lifetime
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
St. Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Actively Recruiting
2
University Health Network
Toronto, Ontario, Canada, M5G 2C4
Actively Recruiting
3
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M6J 1H4
Actively Recruiting
Research Team
B
Benoit H. Mulsant, MD
CONTACT
H
Heather Brooks, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here